Výsledky vyhledávání - "Thatcher Ross Heumann"

A phase II study of atezolizumab (ATEZO) and bevacizumab (BEV) in combination with Y90 TARE in patients (pts) with hepatocellular carcinoma (HCC): Y90+/- BEAT

Autor: Renuka V. Iyer, Michael Petroziello, Nainesh Parikh, Richard D. Kim, Thatcher Ross Heumann, Daniel Brown, Kevin Kim, Yixing Jiang, Suvranu Ganguli, Eric Marks, Beau Toskich, Umair Majeed, Shamar Young, Rachna T. Shroff, Moh'd M. Khushman, Andrew Gunn, Filip Banovac, Aiwu Ruth He

Publikováno v: Journal of Clinical Oncology. 41:TPS629-TPS629

TPS629 Background: The anti–PD-L1 antibody ATEZO prevents PD-L1 from interacting with PD-1 and B7.1, thus reinvigorating antitumor T cell activity. Anti-VEGF BEV can increase dendritic cell maturation, enhance T cell infiltration, and reduce myeloi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::69777b231cf5fc3ca299ec1910d8c0b3
https://doi.org/10.1200/jco.2023.41.4_suppl.tps629

Zobrazit plný text záznamu

ETCTN 10476: A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer

Autor: Thatcher Ross Heumann, Mark Yarchoan, Judy Murray, Hao Wang, John Joseph Wright, Elad Sharon, Gregory B. Lesinski, Nilofer Saba Azad

Publikováno v: Journal of Clinical Oncology. 41:TPS639-TPS639

TPS639 Background: The combination of the MEK inhibitor, Cobimetinib, with the PD-L1 antagonist, Atezolizumab, significantly improved progression-free survival (PFS) compared to Atezolizumab monotherapy in patients with advanced biliary tract cancer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::38249cd74d3b6e6ab79ee90ecaa82a5b
https://doi.org/10.1200/jco.2023.41.4_suppl.tps639

Zobrazit plný text záznamu

A phase I study of a mutant KRAS-targeted long peptide vaccine combined with ipilimumab/nivolumab in resected pancreatic cancer and MMR-proficient metastatic colorectal cancer

Autor: Saurav Daniel Haldar, Thatcher Ross Heumann, Maureen Berg, Anna Ferguson, Su Jin Lim, Hao Wang, Julie Nauroth, Dan Laheru, Elizabeth M. Jaffee, Nilofer Saba Azad, Neeha Zaidi

Publikováno v: Journal of Clinical Oncology. 41:TPS814-TPS814

TPS814 Background: Novel strategies are needed to improve immune responses in “cold” tumors such as pancreatic ductal adenocarcinoma (PDAC) and mismatch repair-proficient colorectal cancer (MMRp CRC). As a frequent oncogenic driver, mutant KRAS (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fdf3bb2b470253e92e14da2ac3ad10b1
https://doi.org/10.1200/jco.2023.41.4_suppl.tps814

Zobrazit plný text záznamu

Neoadjuvant and adjuvant antitumor vaccination alone or combination with PD1 blockade and CD137 agonism in patients with resectable pancreatic adenocarcinoma

Publikováno v: Journal of Clinical Oncology. 40:558-558

558 Background: Utilizing a vaccine that induces and activates host effector T cells and co-administering it with immune modulating agents that enhance anti-tumor T cell activity is a potential strategy for overcoming pancreatic adenocarcinoma’s (P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8ef87447594fb06fd1149f9d7bf2a06d
https://doi.org/10.1200/jco.2022.40.4_suppl.558

Zobrazit plný text záznamu

MLTI-03. FIRST-LINE STEREOTACTIC RADIOSURGERY COMBINED WITH SYSTEMIC TARGETED AND IMMUNE CHECKPOINT INHIBITOR THERAPY IN MELANOMA PATIENTS WITH NEWLY DIAGNOSED BRAIN METASTASES

Autor: Alexandra Sansosti, Akram Habibi, Cameron Beaudreault, Anna C. Pavlick, Rebecca Ye, Kenneth E. Bernstein, Marc Kryger, Thatcher Ross Heumann, Douglas Kondziolka, Peter Wu

Publikováno v: Neuro-oncology Advances

BACKGROUND: Of solid tumors, melanoma has the highest propensity for CNS spread with historic median survivals of 5–8 months following brain metastasis diagnosis. We evaluated the impact of systemic BRAF targeted and immune checkpoint inhibitor (IC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8227e9864cd3487a63465ea40c8fce43
https://doi.org/10.1093/noajnl/vdz014.062

Zobrazit plný text záznamu

First-line stereotactic radiosurgery combined with systemic targeted and immune checkpoint inhibitor therapy in melanoma patients with newly diagnosed brain metastases

Autor: Jeffrey S. Weber, Rebecca Ye, Akram Habibi, Douglas Kondziolka, Peter Wu, Kenneth E. Bernstein, Marc Kryger, Joshua S. Silverman, Cameron Beaudreault, Anna C. Pavlick, Thatcher Ross Heumann, Alexandra Sansosti

Publikováno v: Journal of Clinical Oncology. 37:e13577-e13577

e13577 Background: Of solid tumors, melanoma has the highest propensity for central nervous system spread with historic median survivals of 5-8 months following brain metastasis diagnosis. We evaluated the impact of systemic BRAF targeted and immune

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5eeb8ddb37811bb3a25914913e142c39
https://doi.org/10.1200/jco.2019.37.15_suppl.e13577

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání